Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 12th April 2018 8:15am – 9:30am
Venue	The Committee Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Susan Greene, Senior Pharmacy Technician (SG)
Quorate: Yes / No	Yes
Attendance	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG) Mr P O'Brien, Deputy Chief Pharmacist Dr O Ogunbambi, Consultant Rheumatologist Miss Daniella Gupta, Locality Pharmacist, Medicines Management, Hull NECS (deputy for KMcC) Dr F Umerah, Consultant Anaesthetist Dr A Samson, Infectious Diseases Consultant Dr H Klonin, Consultant Paediatrician Rebecca Howman , Pre-registration Pharmacist, HEY(Guest) Vicky Fernandez, Pre-registration Pharmacist, HEY (Guest)
Apologies	Mr K McCorry, Medicines Management, East Riding Prof M Lind, Vice Chair, Professor of Oncology Mr R Kapur, Vascular Surgeon Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.04.01	**Apologies**	As above.					
2018.04.02	**Declarations of Interest**	None					04/18
2018.04.03	**Minutes of the previous meeting**	The minutes were accepted as a true record.					04/18
2018.04.04	**D&T Attendance 2017-2018**	This report was discussed by the committee. The expected attendance in the ToR was 9/12 months. It was noted that the lay member had not attended for some time, due to illness. Dr Roper had not attended during the year and CCG medical representation was missed. This was to be raised at HERPC. Mrs Wear to be removed, as minutes were now done by Mrs Greene.	SPG to e-mail lay member regarding attendance. CCG medical member to be requested at HERPC.	SPG to send an e-mail SG to add to HERPC agenda and make the amendments	SPG SG	05/18 05/18	
2018.04.05	**D&T Product Requests 2017-2018**	This report was discussed by the committee. It had been a busy year, with 43 new product requests processed by the committee. It was agreed that if a product has a NICE TA, this should be highlighted on the spreadsheet, for future reference.	NICE TA numbers to be added.	SG to amend by adding NICE TAs	SG	05/18	
2018.04.06	**Action Tracker**	**Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable NICE TA492** ML to request application from Dr Butt. ML not present at meeting. **Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer NICE TA 496** ML to request application. ML not present at meeting.	Ongoing. Ongoing.	ML to request ML to request	ML ML	03/18 03/18	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		Lenvatinib with everolimus for previously treated advanced renal cell carcinoma ML to ask for new product request. ML not at meeting.	Ongoing.	ML to request	ML	03/18	
		Ceritinib for untreated ALK-positive non-small-cell lung cancer ML to ask for new product request. ML not at meeting.	Ongoing.	ML to request	ML	03/18	
		Ibrutinib for treating relapsed or refractory mantle cell lymphoma ML to ask for new product request. ML not at meeting.	Ongoing.	ML to request	ML	03/18	
		At this point there was discussion about how D&TC should deal with NICE TAs recommending use within the CDF vs NICE TAs where the drug was previously in use via the CDF. Previously, new cancer drugs were allowed to be used if they were listed on the national CDF list. D&TC then requested a new product request form if they later moved to become NICE TA recommended. D&TC had not received forms for many of these requests, and there was seemingly no incentive for clinicians to fill in the form for a drug which was already in clinical use. It was felt that a better process would be to ask the clinicians to complete the new product request form when NICE had reviewed a new drug and decided to give full approval as a TA, or as a TA recommending use within the CDF. The new product request would then allow Pharmacy to process the drug properly, setting it up on the Ascribe computer, ordering stock, creating the ARIA chemotherapy regimens, ensuring NHSE were informed of predicted use and blueteq was ready, etc.	POB to discuss proposal with relevant colleagues in Clinical Support HG SG to review those NICE TAs where a NPR form had not been received.	POB to discuss with colleagues SG to create list of NICE TAs not on formulary	POB SG	05/18 06/18	
		Tofacitinib for moderate to severe rheumatoid arthritis Clinical pathway had been written - on today's agenda.	Action complete.				04/18
		Fendix Media - Pharma Campaigns on Pattie Intranet DC to feed back in June.	Ongoing.	DC to feed back in June	DC	06/18	
		East Riding and Hull Trusts Joint Respiratory Guidelines for Adults:					

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		• Diagnosis of airways disease • COPD Treatment Pathway • Treatment Of Adult Asthma All had been added to the HERPC agenda.	Action complete.				04/18
		Pirfenidone for treating idiopathic pulmonary fibrosis https://www.nice.org.uk/guidance/ta504 SG to move to formulary, as per NICE TA504.	Action complete.				04/18
		Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma https://www.nice.org.uk/guidance/ta505 ML to ask for new product request. ML not at meeting.	Ongoing.	ML to request	ML	04/18	
		Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C https://www.nice.org.uk/guidance/ta507 SPG had contacted Lorraine Cullen and POB had spoken to her.	Action complete.				04/18
		Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women https://www.nice.org.uk/guidance/ta160 SG had removed strontium from the formulary.	Action complete.				04/18
2018.04.07	**New Product Requests**	**Invertase Syrup – Dr M Nair** This unlicensed product was approved for genetic disaccharide enzyme deficiency. Discussion took place regarding funding for the product. It was felt that as there is joint working with Sheffield, commissioning/funding arrangements would need to be checked.	Approved. POB to check funding and commissioning status.	POB to check funding arrangements	POB	05/18	
		Chloroprocaine Hydrochloride Solution – Dr A Coe This product was approved for spinal anaesthesia where surgery was expected to not exceed 40 minutes.	Approved.	SG to add to formulary	SG	05/18	
		Dimethyl Fumarate – Dr R Zaman This product was approved in line with NICE TA475, subject to receipt of a new product request form that had been signed by the	Approved.	SG to add to formulary	SG	05/18	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		F&W HG Medical Director, Mr Vize. Antonio Ramirez was working with Dermatology to develop a psoriasis treatment flow chart and it was hoped this would be ready for D&T Committee in May.		AM to write to all applicants	AM	05/18	
2018.04.08	**Guidelines**	**Systemic Biological Therapy for Rheumatoid Arthritis** Dr Ogunbambi shared this treatment flow chart with the committee. The committee commended inclusion of all the new biological agents and approved the document.	Approved. To go to HERPC.	SG to add to HERPC agenda	SG	05/18	
2018.04.09	**NICE Guidance March 2018**	Attention deficit hyperactivity disorder: diagnosis and management https://www.nice.org.uk/guidance/ng87	Noted, of relevance to HFT.	No further action			04/18
		Heavy menstrual bleeding: assessment and management https://www.nice.org.uk/guidance/ng88	All drugs/groups on formulary.	No further action			04/18
		Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism https://www.nice.org.uk/guidance/ng89 SPG highlighted that the changes in this guideline would not affect the formulary. However, at Thrombosis Committee it was agreed to hold a meeting to discuss what actions were required, particularly around: 1 Use of rivaroxaban as first line DOAC for elective orthopaedics, 2 Inclusion of 16-18 year olds for VTE risk assessment (which HK would also raise at the relevant paediatrics meetings), 3 VTE risk assessment being done as soon as possible after admission or by the first consultant review.	All drugs/groups on formulary.	No further action			04/18
		Physical activity and the environment https://www.nice.org.uk/guidance/ng90	Noted, for local authorities.	No further action			04/18
		Otitis media (acute): antimicrobial prescribing https://www.nice.org.uk/guidance/ng91	All drugs on formulary.	No further action			04/18
		Stop smoking interventions and services https://www.nice.org.uk/guidance/ng92	All drugs/groups on formulary.	No further action			04/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		Learning disabilities and behaviour that challenges: service design and delivery https://www.nice.org.uk/guidance/ng93	Not about drugs, of relevance to HFT.	No further action			04/18
		Emergency and acute medical care in over 16s: service delivery and organisation https://www.nice.org.uk/guidance/ng94	Noted, not about drugs.	No further action			04/18
		Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee https://www.nice.org.uk/guidance/ta508 POB reported that HEY is not commissioned to provide this specialist service.	Drug non-formulary. Formulary to be annotated that service is not provided at HEY.		SG	05/18	
		Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer https://www.nice.org.uk/guidance/ta509	Pertuzumab on CDF list, trastuzumab on formulary.	ML to request pertuzumab new product request form	ML	05/18	
		Daratumumab monotherapy for treating relapsed and refractory multiple myeloma https://www.nice.org.uk/guidance/ta510 NICE recommended for use within the CDF.	Not on formulary.	ML to request new product request form	ML	05/18	
		Brodalumab for treating moderate to severe plaque psoriasis https://www.nice.org.uk/guidance/ta511 This had already been approved at D&TC prior to the NICE TA publication. The 1p price per syringe PAS scheme will continue for 90 days from the date of the NICE TA.	Already on formulary.	No further action			04/18
		Tivozanib for treating advanced renal cell carcinoma https://www.nice.org.uk/guidance/ta512	Not on formulary.	ML to request new product request form	ML	05/18	
		Obinutuzumab for untreated advanced follicular lymphoma https://www.nice.org.uk/guidance/ta513	Already on formulary.	SG to amend to include	SG	05/18	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
				TA513			
		Regorafenib for previously treated advanced hepatocellular carcinoma https://www.nice.org.uk/guidance/ta514	Not recommended by NICE for this condition.	No further action			04/18
		Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen https://www.nice.org.uk/guidance/ta515	Not recommended by NICE for this condition.	No further action			04/18
		Cabozantinib for treating medullary thyroid cancer https://www.nice.org.uk/guidance/ta516	On formulary CDF list.	ML to request new product request form	ML	05/18	
2018.04.10	**MHRA Drug Safety Update - March 2018**	Daclizumab (Zinbryta▼): suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy	All HEY patients had already been reviewed and the drug stopped.	No further action.			04/18
		Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users	HEY patients were being reviewed	No further action.			04/18
		Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition, eg, cigarettes	Noted.	No further action.			04/18
2018.04.11	**Minutes from the Safe Medication Practice Committee – 24/01/18**	The minutes were circulated for information.	Noted	No further action.			04/18
2018.04.12	**Minutes from the Hull and East Riding Prescribing Committee**	None.					04/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.04.13	**Regional Medicines Optimisation Committee Minutes**	None.					04/18
2018.04.14	**Correspondence received**	SPG had received correspondence from Dr Ming, regarding the new product request for safinamide that had been deferred from the October/17 meeting. The chair of the meeting had written to ask if the predicted usage figures were correct and where safinamide would be used in the treatment of Parkinson's disease. Dr Ming had replied indicating that the numbers predicted were indeed correct, but that safinamide would be almost the last "add on" treatment in patients with severe Parkinson's. Where a MAOI was required, rasagaline or selegiline would be used first. Safinamide would be reserved for patents that had not responded or had side effects to these.	Safinamide new product request now approved.	AM to write to applicant	AM	05/18	
2018.04.15	**Chairs approvals**	**Aprotinin infusion – Mr Cale, Cardiothoracic surgery/ITU request** - Post-CABG surgery bleeding. Dr Umerah to discuss with surgeons and ask for a new product request form, if they wish to use the product in the future for selected patients.	Noted. FU to ask for new product request form if further use is expected.	FU to discuss with surgeons	FU	05/18	
2018.04.16	**Issues to escalate to Operational Quality Committee**	None.					04/18
2018.04 17	**Any Other Business**	None.					04/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.04 18	**Date and Time of Next Meeting**	**Date – Thursday 10th May 2018** **Time – 8.15am - 9.30am** **Venue – Committee Room, Alderson House, HRI**					